Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

PURPOSE: Fremanezumab monoclonal antibody therapy has demonstrated efficacy for chronic migraine (CM) with rapid onset and good tolerability. This subgroup analysis of two clinical trials (Japanese and Korean CM Phase 2b/3 [NCT03303079] and HALO CM Phase 3 [NCT02621931]) aimed to evaluate the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Saigoh, Kazumasa, Takeshima, Takao, Nakai, Masami, Shibasaki, Yoshiyuki, Ishida, Miki, Ning, Xiaoping, Barash, Steve, Isogai, Yuki, Koga, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124568/
https://www.ncbi.nlm.nih.gov/pubmed/37101521
http://dx.doi.org/10.2147/JPR.S393854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124568/
https://www.ncbi.nlm.nih.gov/pubmed/37101521
http://dx.doi.org/10.2147/JPR.S393854

Ejemplares similares